

Human CellExp™ CEACAM6/CD66c, human recombinant

CATALOG #: 7837-10 10 µg
7837-50 50 µg

ALTERNATE NAMES: CEACAM6, CD66c, CEAL, NCA

SOURCE: HEK 293 cells (Lys 35 – Gly 320)

PURITY: ≥ 95% by SDS-PAGE gel

MOL. WEIGHT: This protein rhCEACAM6 is fused with 6xhis tag at C-terminus, has a calculated MW of 32 kDa expressed. The predicted N-terminus is Lys35. Protein migrates as 35-65 kDa in reduced SDS-PAGE resulting from glycosylation.

ENDOTOXIN LEVEL: < 1.0 EU per µg of the rhCEACAM6 by the LAL method.

FORM: Lyophilized

FORMULATION: Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.


STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -20°C or -70°C for up to 3 months. Avoid repeated freezing and thawing cycles. No activity loss was observed after storage in lyophilized state for 1 year (4°C) and after reconstitution under sterile conditions for 3 months (-70°C).

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in PBS, pH 7.4. Do not vortex.

DESCRIPTION: Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial

by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

BIOLOGICAL ACTIVITY: Measured by the ability of the immobilized protein to support the adhesion of calcium ionophore treated human neutrophils. When 2 x 10⁵ cells/well are added to CEACAM6 coated plates (10 µg/mL, 100 µL/well), 45-70% of the cells will adhere after 20 minutes at 37°C.



Human recombinant CEACAM6/CD66c. The purity of rhCEACAM6 was determined by SDS-PAGE of reduced rhCEACAM6 and staining overnight with Coomassie Blue.

RELATED PRODUCTS:

- Human CellExp™ CD223, human recombinant (Cat. No. 7278-10, -50)
- Human CellExp™ CD71, human recombinant (Cat. No. 7279-10, -50)
- Human CellExp™ CD273, human recombinant (Cat. No. 7369-10, -50)
- Human CellExp™ CD33, human recombinant (Cat. No. 7370-10, -50)
- Human CellExp™ CD36, human recombinant (Cat. No. 7371-10, -50)
- Human CellExp™ CD87, human recombinant (Cat. No. 7372-20, -100)
- Human CellExp™ CD360, human recombinant (Cat. No. 7373-20, -100)
- Human CellExp™ CD244, human recombinant (Cat. No. 7374-10, -50)

FOR RESEARCH USE ONLY! Not to be used in humans.

